Gujie Mi

Controlling ferrofluid permeability across the blood-brain barrier model

In the present study, an in vitro blood–brain barrier model was developed using murine brain endothelioma cells (b.End3 cells). Confirmation of the blood–brain barrier model was completed by examining the permeability of FITCDextran at increasing exposure times up to 96 h in serum-free medium and comparing such values with values from the literature. After such confirmation, the permeability of five novel ferrofluid (FF) nanoparticle samples, GGB (ferrofluids synthesized using glycine, glutamic acid and BSA), GGC (glycine, glutamic acid and collagen), GGP (glycine, glutamic acid and PVA), BPC (BSA, PEG and collagen) and CPB (collagen, PVA and BSA), was determined using this blood–brain barrier model. All of the five FF samples were characterized by zeta potential to determine their charge as well as TEM and dynamic light scattering for determining their hydrodynamic diameter. Results showed that FF coated with collagen passed more easily through the blood–brain barrier than FF coated with glycine and glutamic acid based on an increase of 4.5% in permeability. Through such experiments, diverse magnetic nanomaterials (such as FF) were identified for: (1) MRI use since they were less permeable to penetrate the blood–brain barrier to avoid neural tissue toxicity (e.g. GGB) or (2) brain drug delivery since they were more permeable to the blood–brain barrier (e.g. CPB).

Self-assembled arginine-rich peptides as effective antimicrobial agents

Bacteria can adapt to their ever-changing environment to develop a resistance to commonly used antibiotics. This escalating evolution of bacteria coupled with a diminished number of effective antibiotics has caused a global healthcare crisis. New antimicrobials and novel approaches to tackle this problem are urgently needed. Antimicrobial peptides are of particular interest in this endeavor due to their broad spectrum antimicrobial properties as well as ability to combat multi-drug resistant bacteria. Most peptides have both hydrophobic and hydrophilic regions that enable them to be soluble in an aqueous solution, yet can insert into and subsequently disintegrate lipid rich membranes through diverse mechanisms. In this study, a novel class of cationic nanoparticles (formed by the self-assembly of an amphiphilic peptide) were shown to have strong antimicrobial properties against gram-positive bacteria, specifically Staphylococcus aureus, Staphylococcus epidermidis, and methicillin-resistant Staphylococcus aureus (MRSA) with minimal toxicity to human dermal fibroblasts. The particular self-assembled structure tested here included an arginine rich nanoparticle (C17 H35 GR7RGDS or amphiphilic peptide nanoparticles, APNPs) which incorporated seven arginine residues (imparting a positive charge to improve membrane interactions), a hydrophobic block which drove the self-assembly process, and the presence of an amino acid quadruplet arginine-glycine-aspartic acid-serine (RGDS) which may render these nanoparticles capable of attracting healthy cells while competing bacterial adherence to fibronectin, an adhesive protein found on cell surfaces. As such, this in vitro study demonstrated that the presently formulated APNPs should be further studied for a wide range of antibacterial applications where antibiotics are no longer useful.

Synthesis and characterization of biogenic selenium nanoparticles with antimicrobial properties made by Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli, and Pseudomonas aeruginosa : SYNTHESIS AND CHARACTERIZATION OF BIOGENIC SELENIUM NANOPARTICLES

Antimicrobial resistance is a global concern that affects more than two million people each year. Therefore, new approaches to kill bacteria are needed. One of the most promising methodologies may come from metallic nanoparticles, since bacteria may not develop a resistance to these nanostructures as they do for antibiotics. While metallic nanoparticle synthesis methods have been well studied, they are often accompanied by significant drawbacks such as cost, extreme processing conditions, and toxic waste production since they use harsh chemicals such as corrosive agents (hydrazine) or strong acids (hydrochloride acid). In this work, we explored the environmentally safe synthesis of selenium nanoparticles, which have shown promise in killing bacteria. Using Escherichia coli, Pseudomonas aeruginosa, Methicillin-resistance Staphylococcus aureus, and S. aureus, 90-150 nm average diameter selenium nanoparticles were synthesized using an environmentally safe approach. Nanoparticles were characterized using transmission electron microscopy, energy dispersive X-ray spectroscopy to determine the chemical composition, and inductively coupled plasma mass spectrometry to validate chemistry. Nanoparticles were also characterized and tested for their ability to inhibit bacterial growth. A decay in bacterial growth after 24 h was achieved against both S. aureus and E. coli at biogenic selenium nanoparticle concentrations from 25 to 250 µg/mL and showed no significant cytotoxicity effect against human dermal fibroblasts for 24 h. Bacteria were able to synthesize selenium nanoparticles through the use of different functional structures within the organisms, mainly enzymes such as selenite reductases. Therefore, biogenic selenium nanoparticles made by bacteria represent a viable approach to reduce bacteria growth without antibiotics overcoming the drawbacks of synthetic methods that employ toxic chemicals.

Reducing Bacterial Infections and Biofilm Formation Using Nanoparticles and Nanostructured Antibacterial Surfaces

With the rapid spreading of resistance among common bacterial pathogens, bacterial infections, especially antibiotic-resistant bacterial infections, have drawn much attention worldwide. In light of this, nanoparticles, including metal and metal oxide nanoparticles, liposomes, polymersomes, and solid lipid nanoparticles, have been increasingly exploited as both efficient antimicrobials themselves or as delivery platforms to enhance the effectiveness of existing antibiotics. In addition to the emergence of widespread antibiotic resistance, of equal concern are implantable device-associated infections, which result from bacterial adhesion and subsequent biofilm formation at the site of implantation. The ineffectiveness of conventional antibiotics against these biofilms often leads to revision surgery, which is both debilitating to the patient and expensive. Toward this end, micro- and nanotopographies, especially those that resemble natural surfaces, and nonfouling chemistries represent a promising combination for long-term antibacterial activity. Collectively, the use of nanoparticles and nanostructured surfaces to combat bacterial growth and infections is a promising solution to the growing problem of antibiotic resistance and biofilm-related device infections.

Ion-paired pirenzepine-loaded micelles as an ophthalmic delivery system for the treatment of myopia

Myopia is one of the most common ocular disorders for which standard treatments, such as refractive surgery, often involve invasive procedures. Pirenzepine (PRZ), a muscarinic receptor antagonist, has been recognized as a promising candidate for the treatment of myopia, but possesses poor ocular bioavailability. The overall objective of this study was to prepare PRZ-sorbic acid complexes suitable to be encapsulated into micelles with high efficiency for optimal ophthalmic delivery. The results demonstrated that sorbic acid, used as the counter ion, had the most significant effects in increasing the octanol-water distribution coefficient of PRZ as well as improving its corneal permeability in vitro among various counter ions tested. In vivo absorption results showed that a 1.5 times higher bioavailability was achieved by the addition of sorbic acid at a 1:1 ratio. Cytotoxicity studies in vitro and biocompatibility studies in vivo indicated that the micelles did not cause significant toxicities to the eyes.

Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Current therapies present significant limitations. Triptolide (TP) is highly effective against multiple cancers including HCC. However, high toxicity, low water solubility, and unknown therapeutic targets limit its clinical application. Herein, we designed galactosylated-chitosan-TP-nanoparticles (GC-TP-NPs) with high drug loading capacities for targeted delivery to HCC. In addition to a sustained release pattern, an efficient asialoglycoprotein receptor mediated cellular uptake in vitro, and high liver tumor accumulation in vivo, GC-TP-NPs showed lower systemic and male reproductive toxicities than free TP. Importantly, GC-TP-NPs retained the anti-cancer activities of the free TP, exerting the same pro-apoptotic and anti-proliferative effects on HCC cells in vitro, and displayed higher efficacies in reducing tumor sizes in vivo. Further investigation revealed that GC-TP-NPs induced cancer cell apoptosis via blocking TNF/NF-κB/BCL2 signaling. Collectively, GC-TP-NP represents a promising candidate in halting liver cancer progression while minimizing systemic toxicity.

A Status Report on FDA Approval of Medical Devices Containing Nanostructured Materials

Commercialization has been slow since the FDA approved a medical device containing nanomaterials in 1980. In 2017, the FDA released draft guidance to accelerate approval. We highlight here that geographical and structural separation of researchers, manufacturers, and clinical servicers may slow commercialization more than FDA approval.

In vitro and ex vivo systems at the forefront of infection modeling and drug discovery

Abstract Bacterial infections and antibiotic resistant bacteria have become a growing problem over the past decade. As a result, the Centers for Disease Control predict more deaths resulting from microorganisms than all cancers combined by 2050. Currently, many traditional models used to study bacterial infections fail to precisely replicate the in vivo bacterial environment. These models often fail to incorporate fluid flow, bio-mechanical cues, intercellular interactions, host-bacteria interactions, and even the simple inclusion of relevant physiological proteins in culture media. As a result of these inadequate models, there is often a poor correlation between in vitro and in vivo assays, limiting therapeutic potential. Thus, the urgency to establish in vitro and ex vivo systems to investigate the mechanisms underlying bacterial infections and to discover new-age therapeutics against bacterial infections is dire. In this review, we present an update of current in vitro and ex vivo models that are comprehensively changing the landscape of traditional microbiology assays. Further, we provide a comparative analysis of previous research on various established organ-disease models. Lastly, we provide insight on future techniques that may more accurately test new formulations to meet the growing demand of antibiotic resistant bacterial infections.

Controlling permeabilities of ferrofluids with various coatings across the blood-brain barrier

In this study, an in vitro blood-brain barrier model was developed using murine brain endothelioma cells (bEnd.3). By comparing the permeability of FITC-Dextran at increasing exposure times in serum-free medium to such values in the literature, we confirmed that the blood-brain barrier model was successfully established. After such confirmation, the permeability of five ferrofluid (FFs) nanoparticle samples was determined using this model. Results indicated that FFs coated with collagen had better permeability across the blood-brain barrier than FFs coated with glycine or glutamic acid. Through such experiments, magnetic nanomaterials, such as ferrofluids, that are less permeable to the blood brain barrier can be used to decrease neural tissue toxicity and magnetic nanomaterials more permeable to the blood-brain barrier can be used for brain drug delivery.